» Articles » PMID: 36177761

Differential Effects of Glucose-dependent Insulinotropic Polypeptide Receptor/glucagon-like Peptide-1 Receptor Heteromerization on Cell Signaling when Expressed in HEK-293 Cells

Overview
Date 2022 Sep 30
PMID 36177761
Authors
Affiliations
Soon will be listed here.
Abstract

The incretin hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are important regulators of many aspects of metabolism including insulin secretion. Their receptors (GIPR and GLP-1R) are closely related members of the secretin class of G-protein-coupled receptors. As both receptors are expressed on pancreatic β-cells there is at least the hypothetical possibility that they may form heteromers. In the present study, we investigated GIPR/GLP-1R heteromerization and the impact of GIPR on GLP-1R-mediated signaling and vice versa in HEK-293 cells. Real-time fluorescence resonance energy transfer (FRET) and bioluminescence resonance energy transfer (BRET) saturation experiments confirm that GLP-1R and GIPR form heteromers. Stimulation with 1 μM GLP-1 caused an increase in both FRET and BRET ratio, whereas stimulation with 1 μM GIP caused a decrease. The only other ligand tested to cause a significant change in BRET signal was the GLP-1 metabolite, GLP-1 (9-36). GIPR expression had no significant effect on mini-G recruitment to GLP-1R but significantly inhibited GLP-1 stimulated mini-G and arrestin recruitment. In contrast, the presence of GLP-1R improved GIP stimulated mini-G and mini-G recruitment to GIPR. These data support the hypothesis that GIPR and GLP-1R form heteromers with differential consequences on cell signaling.

Citing Articles

Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don't.

Novikoff A, Muller T Physiology (Bethesda). 2024; 39(3):142-156.

PMID: 38353610 PMC: 11368522. DOI: 10.1152/physiol.00032.2023.


G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children.

Dallatana A, Cremonesi L, Trombetta M, Fracasso G, Nocini R, Giacomello L Biomedicines. 2023; 11(6).

PMID: 37371671 PMC: 10295181. DOI: 10.3390/biomedicines11061576.


Variation in responses to incretin therapy: Modifiable and non-modifiable factors.

Austin G, Tomas A Front Mol Biosci. 2023; 10:1170181.

PMID: 37091864 PMC: 10119428. DOI: 10.3389/fmolb.2023.1170181.


Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.

Al-Zaid B, Chacko S, Ezeamuzie C, Bunemann M, Krasel C, Karimian T Pharmacol Res Perspect. 2022; 10(5):e01013.

PMID: 36177761 PMC: 9523454. DOI: 10.1002/prp2.1013.

References
1.
Gabe M, Sparre-Ulrich A, Pedersen M, Gasbjerg L, Inoue A, Brauner-Osborne H . Human GIP(3-30)NH inhibits G protein-dependent as well as G protein-independent signaling and is selective for the GIP receptor with high-affinity binding to primate but not rodent GIP receptors. Biochem Pharmacol. 2018; 150:97-107. DOI: 10.1016/j.bcp.2018.01.040. View

2.
Nauck M, Quast D, Wefers J, Meier J . GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2020; 46:101102. PMC: 8085572. DOI: 10.1016/j.molmet.2020.101102. View

3.
Al-Sabah S, Al-Fulaij M, Shaaban G, Ahmed H, Mann R, Donnelly D . The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively. PLoS One. 2014; 9(9):e106890. PMC: 4156404. DOI: 10.1371/journal.pone.0106890. View

4.
Roed S, Nohr A, Wismann P, Iversen H, Brauner-Osborne H, Knudsen S . Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking. J Biol Chem. 2014; 290(2):1233-43. PMC: 4294488. DOI: 10.1074/jbc.M114.592436. View

5.
Al-Sabah S, Al-Fulaij M, Ahmed H . Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur J Pharmacol. 2014; 741:311-5. DOI: 10.1016/j.ejphar.2014.08.019. View